Alterola Biotech Inc. financial data

Symbol
ABTI on OTC
Industry
Medicinal Chemicals & Botanical Products
Location
47 Hamilton Square, Birkenhead Merseyside, United Kingdom
Fiscal year end
March 31
Former names
JEDEDIAH RESOURCES CORP. (to 11/19/2010)
Latest financial report
10-Q - Q3 2024 - Nov 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 21.4 % +182%
Quick Ratio 0.05 % 0%
Debt-to-equity -143 % -542%
Return On Equity 213 %
Return On Assets -555 % +49%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.46B shares
Common Stock, Shares, Outstanding 1.47B shares +88.6%
Entity Public Float 253K USD -97.6%
Common Stock, Value, Issued 1.47M USD +88.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 64.9K USD
General and Administrative Expense 24K USD +1.6%
Operating Income (Loss) -2.56M USD -75.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -655K USD -46.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -3.26M USD -124%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 82.7K USD
Inventory, Net 1.07K USD +9.64%
Assets, Current 1.15M USD +482%
Deferred Income Tax Assets, Net 187K USD +41.9%
Assets 1.36M USD +174%
Accounts Payable, Current 805K USD +11.5%
Accrued Liabilities, Current 462K USD +87.5%
Liabilities, Current 3.62M USD +43.5%
Liabilities 3.62M USD +43.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 35.6K USD
Retained Earnings (Accumulated Deficit) -13.7M USD -31.1%
Stockholders' Equity Attributable to Parent -2.05M USD -1.63%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.25M USD -8.18%
Liabilities and Equity 1.36M USD +174%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -207K USD -167%
Net Cash Provided by (Used in) Financing Activities 923K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 2B shares 0%
Common Stock, Shares, Issued 1.47B shares +88.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 716K USD +579%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 82.7K USD +809%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.19M USD -438%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 10.2M USD +34.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 189K USD
Interest Expense 337K USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%